Richard S. Lindahl is CFO & VP at Emergent BioSolutions Inc. (EBS). They have made 3 open-market trades across 3 companies since 2012, most recently 2026-06-08.
CIK 0001196632
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $154K since 2012, against 1 sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.